The New Jersey Department of Health currently lists Low Threshold Buprenorphine Induction at Harm Reduction Centers under the Division of Syndemic and Substance Use Services for the FY 2026-2027 grant cycle. The current NJDOH directory shows an application deadline of September 29, 2026. The public directory does not state an exact submission time or timezone.
The program supports New Jersey’s low-threshold buprenorphine model at harm reduction centers. Official New Jersey opioid-program reporting describes this model as providing same-day access to buprenorphine, case management and peer recovery support, with the goal of transitioning participants to maintenance treatment through opioid treatment programs, primary care, office-based addiction treatment, federally qualified health centers or other opioid-use-disorder specialists.
The prior-year controlling NJDOH NOFA, DHST26BUP, limited eligibility to five agencies then funded for Harm Reduction Centers and identified a $2,879,888 program amount. Atlas is not carrying those FY2026 eligibility or funding terms forward as current-year facts. The FY2027 NOFA/RFA must be reviewed to verify current funding, incumbent eligibility, match or cost share, allowable and ineligible costs, equipment and subcontract rules, required forms, submission details, and the exact deadline time.
Atlas assessment: Atlas Opportunity Score 88/100. N9+ Fit Score 74/100, conditional. The Nonagon N9+ remote physical examination platform could have a legitimate supporting role in low-barrier clinical assessment, guided examinations, vitals and telehealth-enabled encounters in fixed or mobile harm-reduction settings, but Atlas is not representing N9+ equipment or services as grant-allowable until the current NOFA/RFA confirms those rules. Dr. Miltie/QC Healthcare should be treated as a potential partner or vendor, not a verified direct applicant, unless the current solicitation says otherwise.